Pediatric phase I trial design using maximum target inhibition as the primary endpoint.
The extent to which a drug inhibits a target responsible for a therapeutic effect is a more rational primary endpoint for dose-finding studies of more selective anticancer drugs than the conventional endpoint of dose-limiting toxicity (DLT) used for cytotoxic agents. An adaptive phase I trial design incorporating maximum target inhibition as the primary endpoint was developed to define the optimal dose of talabostat, a dipeptidyl peptidase (DPP) inhibitor, in children with relapsed or refractory solid tumors. The relationship between dose and effect (percent inhibition of serum DPP-4) was assessed using a maximum effect model. Maximum target inhibition was defined as greater than 90% DPP-4 inhibition in five or more of six patients 24 hours post-dose. If DLT was to occur, the trial would adapt to a traditional phase I design with a more conservative dose escalation. At the 600 microg/m(2) dose level, serum DPP-4 inhibition at 24 hours was 85%. No talabostat-related DLT occurred. The maximum effect model predicted that 1200 microg/m(2) of talabostat would maximally inhibit DPP-4. This adaptive trial design appears to be feasible, safe, and efficient and warrants further evaluation for development of molecularly targeted agents.
Meany
Holly
H
Department of Hematology/Oncology, Children's National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA. hmeany@cnmc.org
Balis
Frank M
FM
Aikin
Alberta
A
Whitcomb
Patricia
P
Murphy
Robert F
RF
Steinberg
Seth M
SM
Widemann
Brigitte C
BC
Fox
Elizabeth
E
D000284:Administration, Oral; D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D019540:Area Under Curve; D001897:Boronic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002648:Child; D002675:Child, Preschool; D015986:Confounding Factors, Epidemiologic; D004151:Dipeptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D010450:Endopeptidases; D005260:Female; D018093:Gelatinases / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy*; D012107:Research Design; D012697:Serine Endopeptidases; D000099167:Fibroblast Activation Protein Alpha
D000970:Antineoplastic Agents; D001897:Boronic Acids; D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D010450:Endopeptidases; D018093:Gelatinases; D008565:Membrane Proteins; D012697:Serine Endopeptidases; D000099167:Fibroblast Activation Protein Alpha; C514044:talabostat
Stat Med. 2005 Jul 30;24(14):2171-81
15909289
Biochimie. 1989 Jun;71(6):757-61
2568856
Clin Cancer Res. 2003 May;9(5):1590-5
12738710
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9
2402505
Invest New Drugs. 2003 May;21(2):243-50
12889742
J Med Chem. 2008 Oct 9;51(19):6005-13
18783201
Cancer Invest. 2006 Oct;24(6):553-61
16982458
Ann Oncol. 2006 Jun;17 Suppl 7:vii128-31
16760275
Cancer Res. 2004 Aug 1;64(15):5471-80
15289357
Clin Pharmacol Ther. 2009 Feb;85(2):127-9
19151636
Oncologist. 2002;7(5):401-9
12401902
Expert Opin Investig Drugs. 2007 Sep;16(9):1459-65
17714031
Ann Oncol. 2002;13 Suppl 4:139-43
12401680
Int Rev Cytol. 2004;235:165-213
15219783